Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer

References

• Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–41
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91; discussion 92
   PubMed Web of Science ®Google Scholar
• Abern M, Owusu R, Anderson M, Rampersaud E, Inman B. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. J Natl Compr Canc Netw 2013;11:477–84
   PubMed Web of Science ®Google Scholar
• Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: Progression-free and disease specific survival with minimum 10-year followup. J Urol 2002;167:494–500; discussion 501
   PubMed Web of Science ®Google Scholar
• Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J Urol 2003;169:96–100; discussion, p 100
   PubMed Web of Science ®Google Scholar
• Dewhirst M, Das S, Stauffer P, Craciunescu O, Vujaskovic Z, Thrall D. Hyperthermia. In: Gunderson L, Tepper J, eds. Clinical Radiation Oncology, 3rd ed. Philadelphia, PA: Elsevier-Saunders; 2012. pp 385–403
   Google Scholar
• Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001;17:1–18
   PubMed Web of Science ®Google Scholar
• Sneed PK, Stauffer PR, Li G, Sun X, Myerson R. Hyperthermia. In: Phillips T, Hoppe R, Roach M, eds. Textbook of Radiation Oncology, 3rd ed. Philadelphia, PA: Elsevier Saunders; 2010. pp 1564–93
   Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–71
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81–93
   PubMed Web of Science ®Google Scholar
• Acton QA. Bladder Cancer: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyEditions, 2013. Available from http://books.google.com/books?id=UBx5eofbuJcC
   Google Scholar
• Oliveira T, Stauffer P, Lee K, Landon C, Wiguins E, Maccarini P, et al. Preclinical dosimetry of magnetic fluid hyperthermia for bladder cancer. Proc SPIE 2013;8584:1656985. doi:10.1117/12.2005623
   Google Scholar
• Oliveira T, Stauffer P, Lee C, Landon C, Etienne W, Ashcraft K, et al. Magnetic fluid hyperthermia for bladder cancer: A preclinical dosimetry study. Int J Hyperthermia 2013;29:835–44
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5
   Google Scholar
• Yuan Y, Cheng KS, Craciunescu OI, Stauffer PR, Maccarini PF, Arunachalam K, et al. Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. Med Phys 2012;39:1170–81
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez-Gonzalez D, van Rhoon GC, van Dijk JDP, van Putten WLJ, Hart AAM. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Lancet 2000;355:1119–25
   PubMed Web of Science ®Google Scholar
• Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 2009;25:3–20
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003;19:267–94
   PubMed Web of Science ®Google Scholar
• Franckena M, Fatehi D, de Bruijne M, Canters RA, van Norden Y, Mens JW, et al. Hyperthermia dose–effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer 2009;45:1969–78
   PubMed Web of Science ®Google Scholar